[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-unknown-primary-site\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-unknown-primary-site":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,86,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100651508","phase-2-a-phase-iiiii-study-of-f520-combined-with-paclitaxel-plus-carboplatin-in-the-treatment-of-cancer-of-unknown-primary-cup-100651508",false,"NCT07761429","A Phase II\u002FIII Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II\u002FIII Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary","Inclusion Criteria:\n\n* Age 18-75 years (inclusive), any gender Histopathologically confirmed adenocarcinoma, squamous cell carcinoma, poorly differentiated carcinoma, or undifferentiated carcinoma of metastatic lesions Diagnosis of CUP after standard evaluation (see Appendix 4) No prior systemic therapy for CUP At least one measurable lesion per RECIST 1.1 criteria Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 Investigator-assessed life expectancy ≥3 months\n\nAdequate organ function as follows (no blood products or hematopoietic growth factors within 14 days before first dose):\n\nHematology: ANC ≥1.5×10⁹\u002FL; Platelet count ≥90×10⁹\u002FL; Hemoglobin (Hb) ≥90 g\u002FL Liver Function: AST, ALT ≤2.5×ULN; Total bilirubin (TBIL) ≤1.5×ULN; If liver metastases present: AST and ALT ≤5×ULN, TBIL ≤3×ULN Renal Function: Serum creatinine (Cr) ≤1.25×ULN Coagulation: INR ≤1.5×ULN and APTT ≤1.5×ULN Understanding of study procedures and content, and voluntary signed informed consent\n\nExclusion Criteria:\n\n* CUP patients who, in the investigator's judgment, are candidates for local curative treatment Histopathologically confirmed neuroendocrine carcinoma or germ cell tumor of metastatic lesions Prior genetic testing (including but not limited to NGS) showing NTRK fusion-positive, ALK fusion-positive, EGFR sensitizing mutations, BRAF mutations suitable for molecular targeted therapy, or MSI-H\u002FdMMR Genetic testing (including but not limited to 90-gene assay) suggesting possible colorectal, renal, or breast cancer origin (excluding triple-negative breast cancer) Prior treatment with taxanes, platinum-based chemotherapy, and\u002For prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1) or any tumor immunotherapy Received chemotherapy, radiotherapy, biologic therapy, endocrine therapy, targeted therapy, or immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) before enrollment Primary and\u002For metastatic central nervous system (CNS) malignancies or carcinomatous meningitis Required systemic corticosteroids (equivalent to \\>10 mg prednisone\u002Fday) or other immunosuppressive drugs within 2 weeks before enrollment or during study. Exception: topical or inhaled corticosteroids, or short-term (≤7 days) corticosteroids for prevention or treatment of non-autoimmune, infrequent allergic diseases Prior anti-tumor treatment-related adverse events not recovered to NCI-CTCAE V5.0 (or later) Grade ≤1 or levels specified in inclusion\u002Fexclusion criteria (except toxicities judged by investigator to have no safety risk, such as alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement) History of other malignancy within past 5 years, except locally curable cancers (melanoma in situ, cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder carcinoma in situ, superficial breast carcinoma in situ) Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage Known interstitial lung disease or non-infectious pneumonia, currently symptomatic or previously requiring systemic corticosteroids, which in the investigator's judgment may affect toxicity assessment or management related to study treatment History of organ transplantation or allogeneic bone marrow transplantation, or autologous stem cell transplantation within 3 months before first dose Major surgery within 4 weeks before first dose or not recovered from surgery before enrollment (excluding diagnostic surgery) Known positive HIV test history or known AIDS; Positive syphilis screening (specific antibody positive with non-specific antibody negative and clinically confirmed non-active infection excluded); HBsAg and\u002For HBcAb positive with HBV-DNA ≥200 IU\u002FmL (or 1000 cps\u002FmL); HCV antibody positive with detectable HCV-RNA indicating viral replication Uncontrolled or severe cardiovascular disease, NYHA Class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months before first dose; Uncontrolled hypertension (systolic ≥160 mmHg and\u002For diastolic ≥100 mmHg despite treatment) Serious concomitant diseases at screening that compromise patient safety or ability to complete the study \\[e.g., active autoimmune disease, active infection (e.g., active tuberculosis), severe psychiatric disease, severe neurological disease, severe endocrine disease (e.g., Type 1 diabetes, drug-uncontrolled Type 2 diabetes), or any other condition\\] Received any other investigational drug\u002Fdevice within 4 weeks before first dose History of drug abuse or alcohol abuse within 6 months before first dose Received live or attenuated live vaccines within 4 weeks before first dose or planned during study History of severe allergy, or known hypersensitivity to macromolecular protein preparations\u002Fmonoclonal antibodies, or any study drug components Pregnant or lactating women; Women of childbearing potential or men with partners of childbearing potential who do not agree to use medically accepted effective contraception (e.g., intrauterine device or condoms) during study and for 6 months after last study drug administration Judged by investigator as unsuitable for enrollment","ALL","18 Years","75 Years",{"count":20,"type":21},402,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The purpose of this study is to evaluate the efficacy and safety of F520 combined with paclitaxel plus carboplatin as first-line treatment for cancer of unknown primary.This study consists of two parts, with a total planned enrollment of 402 patients.Primary Endpoint is Objective Response Rate (ORR) assessed by Independent Review Committee (IRC) based on RECIST 1.1 Secondary Endpoints included ORR、PFS、DOR；Incidence and severity of Adverse Events (AE), Serious Adverse Events (SAE), and abnormal laboratory parameters.",[28],"Cancer of Unknown Primary Site",[30,31],"F520","CUP","RECRUITING","2026-08-10",{"date":35,"type":36},"2026-08-12","ACTUAL",{"date":38,"type":36},"2026-07-08",{"date":40,"type":21},"2028-04",{"name":42,"class":43},"Shandong New Time Pharmaceutical Co., LTD","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":44},"100401235","tcf-001-track-target-rare-cancer-knowledge-study-100401235","NCT04504604","TCF-001 TRACK (Target Rare Cancer Knowledge) Study","TRACK","INCLUSION CRITERIA\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study related blood draws and assessments for the duration of the study.\n* Individuals who are 18 years old or older at the time of consent.\n* Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.\n* May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival specimen tested must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.\n* Willingness to provide existing archived and\u002For newly collected tissue resulting from standard of care procedures and blood samples for genomic profiling. If the submitted sample is determined to be insufficient for testing, the patient will be considered to be a screen failure.\n* For archival tissue to be used for comprehensive genomic profiling for the present study, that specimen must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.\n* Willingness to provide clinical and medical information to the study team as required.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Ability to read, write and communicate in English.\n* Ability to review and sign a web-based informed consent form, or review and sign an informed consent form in treating physician office.\n* Resides within the United States.\n\nEXCLUSION CRITERIA\n\n* Participants who are unable to provide informed consent.\n* Participants who are 17 years of age or younger.\n* Participants who are unable to comply with the study procedures.\n* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.\n* Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician.\n* Pregnancy or breastfeeding.\n* Any unlisted criteria at the discretion of the treating physician.",{"count":53,"type":21},400,[55],"NA","This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.",[58,59,28],"Rare Cancers","Cholangiocarcinoma",[61,62,63,64,65,66,67,68,69,70,71,72,73,74,75],"genomics","precision medicine","molecular tumor board","remote participation","targeted therapy","patient reported outcomes","understudied diseases","comprehensive genomic profiling","virtual","next generation sequencing","liquid biopsies","tumor biopsies","cell-free DNA","biomarker testing","solid tumors","2026-05-21",{"date":78,"type":36},"2026-05-26",{"date":80,"type":36},"2020-10-01",{"date":82,"type":21},"2028-12",{"name":84,"class":85},"TargetCancer Foundation","OTHER",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":97,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":44},"100621618","18f-fapi-pet-in-cancers-of-unknown-primary-site-100621618","NCT07372963","18F-FAPI PET in Cancers of Unknown Primary Site","Prospective Clinical Study and Exploration of 18F-FAPI PET\u002FCT Imaging in Cancers of Unknown Primary Site","Inclusion Criteria:\n\n1. Patients with clinical or imaging suspicion of cancer of unknown primary origin.\n2. Patients with 18F FAPI PET scans.\n\nExclusion Criteria:\n\n1. Concurrent presence of other active malignant tumors or a history of other malignant tumors within the past 5 years;\n2. Severe uncontrollable diseases or active infections;\n3. Ineligible participants for project informed consent.\n4. Pregnant and lactating women.","20 Years","85 Years",{"count":96,"type":21},120,"3 Years","OBSERVATIONAL","This study aims to evaluate the diagnostic efficacy, therapeutic assessment, prognostic analysis, and impact on clinical treatment decisions of 18F-FAPI PET\u002FCT in patients with cancer of unknown primary.",[28],"NOT_YET_RECRUITING","2026-01-20",{"date":104,"type":36},"2026-01-28",{"date":106,"type":21},"2026-02-01",{"date":108,"type":21},"2028-12-31",{"name":110,"class":85},"First Affiliated Hospital of Zhejiang University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100621083","the-norcup-trial-improving-prognosis-and-personalized-treatment-in-cancer-of-unknown-primary-cup-100621083","NCT07366008","The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)","NorCUP","Inclusion Criteria:\n\n* ECOG PS 0-2.\n* Life expectancy minimum 3 months.\n* Radiologically verified metastatic disease (CT thorax\u002Fabdomen\u002Fpelvis) with no radiological signs of primary tumor.\n* Histologically verified metastatic disease of unknown primary. Morphological and immunohistochemical findings suggesting a possible, but not definitive, origo is eligible.\n* Eligible histologies include adenocarcinoma, squamous cell carcinoma, poorly and undifferentiated carcinoma and undifferentiated neoplasms.\n* Clinically relevant endoscopic examinations have been performed as indicated by clinical, radiological and pathological findings, without identification of a primary tumor.\n* Clinically relevant supplementary radiological examinations have been performed as indicated by clinical, radiological and pathological findings, with no radiological signs of primary tumor (e.g. PET\u002FCT, mammography\u002FMR mammae).\n* Metastatic lesion available for biopsy. Protocol deviation may be allowed if lesion is not technically available for biopsy. For patients with metastatic lesion technically available for biopsy, the patient must be deemed medically fit to undergo a metastatic biopsy, as assessed by the investigator.\n* Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria:\n\n* Patients with any clinically significant medical or psychiatric condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.\n* Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n* Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.",{"count":119,"type":21},350,[55],"The goal of this clinical trial is to improve diagnosis and treatment strategies for patients with Cancer of Unknown Primary (CUP) by using advanced molecular profiling to identify the likely tumor origin and guide therapy.\n\nThe main questions it aims to answer are:\n\nCan comprehensive molecular profiling help determine the origin of CUP tumors? Does identifying the tumor origin improve treatment choices and survival outcomes compared to historical data?\n\nParticipants will:\n\n* Undergo a new biopsy to collect tumor tissue for advanced analyses.\n* Provide blood samples for circulating tumor DNA (cfDNA\u002FctDNA) analyses.\n* Provide a fecal sample for microbiome analysis.\n* Have their tumor tissue analyzed using:\n\nMethylation profiling and comprehensive gene panel testing.\n\n* Have the results reviewed in a specialized CUP molecular MDT meeting to determine the likely tumor origin and guide treatment.\n* Have their tumor tissue samples biobanked for further exploratory whole genome sequencing (WGS) and RNA sequencing.",[28],[124,125],"cancer of unknown primary site","neoplasms, unknown primary","2026-01-16",{"date":128,"type":36},"2026-01-26",{"date":130,"type":21},"2026-01",{"date":132,"type":21},"2033-01",{"name":134,"class":85},"Haukeland University Hospital",6]